Results 141 to 150 of about 602,267 (275)

[Persistent neutropenia]

open access: yes, 2010
We report the case of a 72-old patient with persistent neutropenia diagnosed during investigation of sialadenitis. Further examination led to the diagnosis of immune neutropenia and systemic lupus erythematosus.
Oestmann, Andreas   +3 more
core  

Overall Survival Benefit and Long‐Term Safety of Romiplostim in Persistent Chemotherapy‐Induced Thrombocytopenia

open access: yes
American Journal of Hematology, Volume 101, Issue 12, Page 2957-2960, December 2026.
Andrew B. Song, Gerald A. Soff
wiley   +1 more source

Total Neoadjuvant Treatment for Esophageal Adenocarcinoma With Oligometastases: TNT‐OES‐1 Trial

open access: yesInternational Journal of Cancer, Volume 159, Issue 10, Page 2552-2561, 15 November 2026.
Total neoadjuvant therapy could combine the potentially strong systemic effect of FLOT chemotherapy with the good locoregional control of CROSS chemoradiotherapy. While total neoadjuvant therapy is increasingly used in rectal cancer, its potential in gastroesophageal cancer remains largely unexplored.
Charlène J. van der Zijden   +12 more
wiley   +1 more source

PANoptosis in the pathogenesis of myelodysplastic syndromes

open access: yesMolecular Oncology, Volume 20, Issue 11, Page 2584-2610, November 2026.
PANoptosis, a combination of three types of programmed cell death, is mediated by a large protein complex called a PANoptosome. In healthy bone marrow hematopoietic cells, PANoptosis is restricted by inhibitory signaling. In MDS, bone marrow cells become sensitive to the PANoptotic stimuli due to the aberrant inactivation of inhibitory signaling or ...
Rohit Thalla   +4 more
wiley   +1 more source

Severe congenital cyclic neutropenia: A case report. [PDF]

open access: yesInt J Appl Basic Med Res, 2016
Patil VH, Hugar SM, Balikai G, Patil S.
europepmc   +1 more source

Real‐World Outcomes of Midostaurin Plus Intensive Chemotherapy in FLT3‐Mutated AML: The PETHRATIFY Study

open access: yesAmerican Journal of Hematology, Volume 101, Issue 11, Page 2812-2826, November 2026.
ABSTRACT Mutations in FLT3 are present in approximately 30% of patients with AML. The addition of midostaurin (MIDO) to intensive chemotherapy (IC) became standard of care following the RATIFY trial, but comprehensive real‐world data spanning the full adult age spectrum and including both FLT3‐ITD and FLT3‐TKD mutations remain limited.
Mónica Alejandra Romero Riquelme   +49 more
wiley   +1 more source

Real‐World Validation of the MAGIC‐D Index in Unresectable Biliary Tract Cancer Treated With Durvalumab Plus Chemotherapy

open access: yesCancer Medicine, Volume 15, Issue 11, November 2026.
Real‐world Validation of the MAGIC‐D Index. The MAGIC‐D index was validated using real‐world data from patients with unresectable BTC who received durvalumab‐chemotherapy at Tongji Hospital. The risk stratification ability of the MAGIC‐D index for patient survival was improved after incorporating Ki67 and CA 19‐9.
Tianao Zhan   +9 more
wiley   +1 more source

Neoadjuvant Therapy for Non‐Small Cell Lung Cancer: Recent Advances and Future Directions

open access: yesCancer Medicine, Volume 15, Issue 11, November 2026.
ABSTRACT Neoadjuvant therapy has become an integral component of the multidisciplinary management of resectable non–small cell lung cancer (NSCLC). The introduction of immune checkpoint inhibitors (ICIs) has transformed the perioperative treatment landscape by improving pathological response rates, reducing the risk of recurrence, and offering the ...
Hao An   +15 more
wiley   +1 more source

Shortened Obinutuzumab Infusion Is Safe and Reduces Chair Time in Frontline Treatment of Chronic Lymphocytic Leukemia: A Real‐World Study

open access: yesCancer Medicine, Volume 15, Issue 11, November 2026.
In treatment‐naïve CLL, a shortened obinutuzumab infusion was as safe as standard infusion, did not increase infusion‐related reactions, and significantly reduced chair time, improving outpatient unit efficiency. ABSTRACT Background Obinutuzumab‐based regimens are established frontline treatments for chronic lymphocytic leukemia (CLL), but infusion ...
Dominika Écsiová   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy